Migdal Insurance & Financial Holdings Ltd. Exact Sciences Corp Transaction History

Migdal Insurance & Financial Holdings Ltd.

$6.18 Billion
Q3 2024

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 04, 2021	SELL	$93.66 - $139.27 $486,095 - $722,811	-5,190 Closed	0 $0
Q1 2021 May 04, 2021	BUY	$116.57 - $155.01 $375,471 - $499,287	3,221 Added 163.59%	5,190 $684,000
Q4 2020 Feb 08, 2021	SELL	$99.61 - $142.12 $817,100 - $1.17 Million	-8,203 Reduced 80.64%	1,969 $261,000
Q3 2020 Nov 05, 2020	SELL	$72.92 - $102.01 $642,716 - $899,116	-8,814 Reduced 46.42%	10,172 $1.04 Million
Q2 2020 Aug 11, 2020	BUY	$55.75 - $92.75 $345,315 - $574,493	6,194 Added 48.42%	18,986 $1.65 Million
Q1 2020 May 12, 2020	SELL	$37.9 - $104.44 $20,276 - $55,875	-535 Reduced 4.01%	12,792 $742,000
Q4 2019 Feb 13, 2020	BUY	$77.66 - $99.74 $143,593 - $184,419	1,849 Added 16.11%	13,327 $1.23 Million
Q3 2019 Nov 12, 2019	BUY	$90.37 - $122.49 $310,420 - $420,753	3,435 Added 42.71%	11,478 $1.04 Million
Q2 2019 Aug 08, 2019	BUY	$89.51 - $118.04 $208,737 - $275,269	2,332 Added 40.83%	8,043 $949,000
Q1 2019 May 01, 2019	BUY	$61.98 - $96.5 $353,967 - $551,111	5,711 New	5,711 $495,000

Others Institutions Holding EXAS

# of Institutions

676

Shares Held

162M

Call Options Held

2.58M

Put Options Held

2.19M

Vanguard Group Inc Valley Forge, PA

17.8M
Shares

$1.01 Billion
0.02% of portfolio
Capital World Investors Los Angeles, CA

15.8M
Shares

$905 Million
0.17% of portfolio
Wellington Management Group LLP Boston, MA

14.3M
Shares

$818 Million
0.18% of portfolio
Black Rock Inc. New York, NY

12.1M
Shares

$689 Million
0.01% of portfolio
State Street Corp Boston, MA

6.68M
Shares

$381 Million
0.02% of portfolio

View Full List

About EXACT SCIENCES CORP

Ticker EXAS
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 176,960,000
Market Cap $10.1B
Description
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...

More about EXAS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Migdal Insurance & Financial Holdings Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Migdal Insurance & Financial Holdings Ltd. with notifications on news.

Account